Your browser doesn't support javascript.
loading
64Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy.
Hicks, Rodney J; Jackson, Price; Kong, Grace; Ware, Robert E; Hofman, Michael S; Pattison, David A; Akhurst, Timothy A; Drummond, Elizabeth; Roselt, Peter; Callahan, Jason; Price, Roger; Jeffery, Charmaine M; Hong, Emily; Noonan, Wayne; Herschtal, Alan; Hicks, Lauren J; Hedt, Amos; Harris, Matthew; Paterson, Brett M; Donnelly, Paul S.
Afiliação
  • Hicks RJ; Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia rod.hicks@petermac.org.
  • Jackson P; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
  • Kong G; Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Ware RE; Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Hofman MS; Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Pattison DA; Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Akhurst TA; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
  • Drummond E; Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Roselt P; Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Callahan J; Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Price R; Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Jeffery CM; Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Hong E; Medical Technology and Physics, Sir Charles Gairdner Hospital, Nedlands, Washington, Australia.
  • Noonan W; Medical Technology and Physics, Sir Charles Gairdner Hospital, Nedlands, Washington, Australia.
  • Herschtal A; Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Hicks LJ; Liverpool Hospital, Liverpool, New South Wales, Australia.
  • Hedt A; Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Harris M; Mercy Hospital for Women, Heidelberg, Victoria, Australia rod.hicks@petermac.org.
  • Paterson BM; Clarity Pharmaceuticals Ltd., Eveleigh, New South Wales, Australia.
  • Donnelly PS; Clarity Pharmaceuticals Ltd., Eveleigh, New South Wales, Australia.
J Nucl Med ; 60(6): 777-785, 2019 06.
Article em En | MEDLINE | ID: mdl-30442752
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Octreotida / Receptores de Peptídeos / Tumores Neuroendócrinos / Compostos Radiofarmacêuticos / Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada Tipo de estudo: Observational_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Octreotida / Receptores de Peptídeos / Tumores Neuroendócrinos / Compostos Radiofarmacêuticos / Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada Tipo de estudo: Observational_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article